Key Takeaways In late 2023, we wrote about how we thought that after equity performance challenges for the better part of two years, this year could encapsulate a “comeback” for biotech shares. If investors judged the veracity of that statement based on the share price performance of publicly listed biotech companies, it has so far proved […]
↧